Catabasis Pharmaceuticals, Inc. (CATB) belonging to the Medical sector has declined -2.86% and closed its last trading session at $1.7.
The company reported its EPS on 03/16/2017. Currently, the stock has a 1 Year Price Target of $6.9.
The consensus recommendation, according to Zacks Investment research, is 1.5. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 1.5 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1 and 1 respectively.
Catabasis Pharmaceuticals, Inc. on 03/16/2017 reported its EPS as $-0.54 with the analysts projecting the EPS of the stock as $-0.65. The company beat the analyst EPS Estimate with the difference of $0.11. This shows a surprise factor of 16.9%.
Many analysts have provided their estimated foresights on Catabasis Pharmaceuticals, Inc. Earnings, with 5 analysts believing the company would generate an Average Estimate of $-0.52.
Whereas they predicted High and Low Earnings Estimate as $-0.46 and $-0.63 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.63.
For the Current Quarter, the growth estimate for Catabasis Pharmaceuticals, Inc. is 17.5%, while for the Next Quarter the stock growth estimate is 18%.
The Company got Downgrade by Citigroup on 2-Feb-17 from Buy to Neutral.
Insider Trades for Catabasis Pharmaceuticals, Inc. show that the latest trade was made on 29 Jun 2015 where Medimmune Ventures Inc, the Beneficial Owner of More than 10% Class completed a transaction type “Buy” in which 223439 shares were traded at a price of $12.
Over the period of 6 months, Insider Purchases show a total of 4 transaction in which 1250000 shares were traded.
5 analysts projected Price Targets for Catabasis Pharmaceuticals, Inc.. The analysts believe that the company stock price could grow as high as $14. The Low Price target projection by analysts is $1.5 and the Mean Price Target is $6.9.
Catabasis Pharmaceuticals, Inc. (CATB) has the market capitalization of $20.67 Million. The company rocked its 52-Week High of $7.89 on Sep 29, 2016 and touched its 52-Week Low of $1.08 on Feb 1, 2017.
The stock has Return on Assets (ROA) of -69.6 percent. Return on Equity (ROE) stands at -91.1% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of -52.91 Percent. The company has Beta Value of 0 and ATR value of 0.2. The Weekly and Monthly Volatility stands at 28.29% and 11.00%.